S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
Fed's Shocking New Plan to Control Your Money (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Fed's Shocking New Plan to Control Your Money (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
Fed's Shocking New Plan to Control Your Money (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Fed's Shocking New Plan to Control Your Money (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
Fed's Shocking New Plan to Control Your Money (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Fed's Shocking New Plan to Control Your Money (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
Fed's Shocking New Plan to Control Your Money (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Fed's Shocking New Plan to Control Your Money (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
NASDAQ:AXGN

AxoGen - AXGN Stock Forecast, Price & News

$9.22
+0.16 (+1.77%)
(As of 03/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$9.13
$9.42
50-Day Range
$7.53
$10.95
52-Week Range
$6.87
$13.66
Volume
160,778 shs
Average Volume
251,025 shs
Market Capitalization
$392.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00

AxoGen MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
84.4% Upside
$17.00 Price Target
Short Interest
Bearish
3.37% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.70mentions of AxoGen in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$344,052 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.78) to ($0.70) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

631st out of 995 stocks

Electromedical Equipment Industry

12th out of 24 stocks


AXGN stock logo

About AxoGen (NASDAQ:AXGN) Stock

Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm's products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.

Receive AXGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter.

AXGN Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
AxoGen (NASDAQ:AXGN) Now Covered by Analysts at StockNews.com
AxoGen Full Year 2022 Earnings: EPS Beats Expectations
The "King Of Quants" sees 10X potential...
Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...
AxoGen: Rally Looks To Be Exhausted, Revise To Hold
See More Headlines
Receive AXGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter.

AXGN Company Calendar

Last Earnings
11/02/2021
Today
3/27/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXGN
Employees
428
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.00
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+84.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-28,950,000.00
Pretax Margin
-20.89%

Debt

Sales & Book Value

Annual Sales
$138.58 million
Book Value
$2.39 per share

Miscellaneous

Free Float
39,403,000
Market Cap
$393.20 million
Optionable
Optionable
Beta
0.54

Key Executives

  • Karen L. ZaderejKaren L. Zaderej
    Chairman, President & Chief Executive Officer
  • Mike Donovan
    Vice President-Operations
  • Peter J. Mariani
    Chief Financial Officer & Executive Vice President
  • Erick Wayne DeVinney
    Vice President-Clinical & Translational Sciences
  • Ivica Ducic
    Medical Director













AXGN Stock - Frequently Asked Questions

Should I buy or sell AxoGen stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AXGN shares.
View AXGN analyst ratings
or view top-rated stocks.

What is AxoGen's stock price forecast for 2023?

4 equities research analysts have issued twelve-month price objectives for AxoGen's shares. Their AXGN share price forecasts range from $15.00 to $20.00. On average, they expect the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 84.2% from the stock's current price.
View analysts price targets for AXGN
or view top-rated stocks among Wall Street analysts.

How have AXGN shares performed in 2023?

AxoGen's stock was trading at $9.98 at the start of the year. Since then, AXGN shares have decreased by 7.5% and is now trading at $9.23.
View the best growth stocks for 2023 here
.

Are investors shorting AxoGen?

AxoGen saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 1,360,000 shares, an increase of 19.3% from the February 28th total of 1,140,000 shares. Based on an average daily trading volume, of 238,400 shares, the days-to-cover ratio is presently 5.7 days. Approximately 3.4% of the shares of the company are short sold.
View AxoGen's Short Interest
.

When is AxoGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our AXGN earnings forecast
.

How were AxoGen's earnings last quarter?

AxoGen, Inc. (NASDAQ:AXGN) released its earnings results on Tuesday, November, 2nd. The medical equipment provider reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.05. The medical equipment provider earned $31.20 million during the quarter, compared to analysts' expectations of $34.65 million. AxoGen had a negative trailing twelve-month return on equity of 19.05% and a negative net margin of 20.88%. During the same period in the previous year, the company posted ($0.04) EPS.

What guidance has AxoGen issued on next quarter's earnings?

AxoGen updated its FY 2023 earnings guidance on Tuesday, March, 14th. The company provided EPS guidance of for the period. The company issued revenue guidance of $154.00 million-$159.00 million, compared to the consensus revenue estimate of $158.94 million.

What is Karen Zaderej's approval rating as AxoGen's CEO?

19 employees have rated AxoGen Chief Executive Officer Karen Zaderej on Glassdoor.com. Karen Zaderej has an approval rating of 100% among the company's employees. This puts Karen Zaderej in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at AxoGen to a friend.

What other stocks do shareholders of AxoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Advanced Micro Devices (AMD), Bank of America (BAC), Intelsat (I), Intel (INTC), Micron Technology (MU), Xilinx (XLNX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), NVIDIA (NVDA) and Fossil Group (FOSL).

What is AxoGen's stock symbol?

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

Who are AxoGen's major shareholders?

AxoGen's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (8.39%), First Light Asset Management LLC (5.61%), Bank of America Corp DE (4.30%), Point72 Asset Management L.P. (4.29%), William Blair Investment Management LLC (3.47%) and Soleus Capital Management L.P. (1.79%). Insiders that own company stock include Angelo Scopelianos, Erick Wayne Devinney, Gregory Gene Freitag, Isabelle Billet, Karen L Zaderej, Karen L Zaderej, Maria D Martinez, Michael Patrick Donovan and Peter J Mariani.
View institutional ownership trends
.

How do I buy shares of AxoGen?

Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AxoGen's stock price today?

One share of AXGN stock can currently be purchased for approximately $9.23.

How much money does AxoGen make?

AxoGen (NASDAQ:AXGN) has a market capitalization of $393.20 million and generates $138.58 million in revenue each year. The medical equipment provider earns $-28,950,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis.

How many employees does AxoGen have?

The company employs 428 workers across the globe.

How can I contact AxoGen?

AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The official website for the company is www.axogeninc.com. The medical equipment provider can be reached via phone at (386) 462-6800, via email at investorrelations@axogeninc.com, or via fax at 386-462-6801.

This page (NASDAQ:AXGN) was last updated on 3/28/2023 by MarketBeat.com Staff